From the Journals

SABCS Highlights: Advances in Oral SERD's for Breast Cancer

Harold Burstein, MD, PhD, and Rinath M. Jeselsohn, MD, discuss the lidERA, evERA, and EMBER-3 trials researching oral selective estrogen receptor degraders (SERDs).

  • March 17, 2026

Share

  • 1

    SERDs are designed to target estrogen receptors in breast cancer.

  • 2

    Trials lidERA, evERA, and EMBER-3 focus on the effectiveness of oral SERDs.

  • 3

    These trials aim to improve treatment outcomes in hormone receptor-positive breast cancer.

  • 4

    Harold Burstein and Rinath M. Jeselsohn lead discussions on the results.

  • 5

    The research indicates potential advances in therapies for advanced breast cancer patients.

Original Source(s)

SABCS Highlights: Advances in Oral SERD's for Breast Cancer

  • March 17, 2026

Related Content

2025 San Antonio Breast Cancer Symposium Recap

Harold Burstein, MD, PhD, summarizes important breakthroughs presented at the 2025 San Antonio Breast Cancer Symposium.

  • March 17, 2026

SABCS 2025 Highlights: Patient Perspective

Lindsay Northrop, breast cancer survivor and patient advocate at Dana-Farber, talks with Harold Burstein, MD, PhD, about how recent advances in breast cancer research presented at the 2025 San Antonio Breast Cancer Symposium will impact patient care.

  • March 17, 2026

SABCS 2025 Highlights: Hormone Replacement Therapy for Breast Cancer

Harold Burstein, MD, PhD, and Wendy Y. Chen, MD, MPH, discuss research in hormone replacement therapy for breast cancer that was presented at the 2025 San Antonio Breast Cancer Symposium.

  • March 17, 2026